Consensus for 2024 revenue is $148.4M. Raises 2024 adjusted EBITDA view to $2M-$5M from (22M)-$3M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on HRTX: Heron Therapeutics Inc (HRTX) Q3 Earnings Cheat Sheet Heron Therapeutics Strengthens Leadership with New Board Appointment Heron Therapeutics reaffirms availability of Cinvant, Sustol and Aponvie Heron Therapeutics: FDA approves prior supplement application for ZYNRELEF Disclaimer & DisclosureReport an Issue
